Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis

(2016) Jordi Río et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

(2014) Mark S. Freedman et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

(2014) Jordi Río et al.   Multiple Sclerosis Journal

Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature

(2013) Sunil Mahurkar et al.   AUTOIMMUNITY REVIEWS

Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study

(2013) A. Shirani et al.   EUROPEAN JOURNAL OF NEUROLOGY

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

(2013) Luca Prosperini et al.   Multiple Sclerosis Journal

Assessing treatment response to interferon- : Is there a role for MRI?

(2013) R. Dobson et al.   NEUROLOGY

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta

(2012) Robert A. Bermel et al.   ANNALS OF NEUROLOGY

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

(2012) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

(2011) S Cook et al.   Multiple Sclerosis Journal

Natural History of Multiple Sclerosis: Early Prognostic Factors

(2011) Ellen M. Mowry   NEUROLOGIC CLINICS

Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study

(2011) Kottil Rammohan et al.   Multiple Sclerosis and Related Disorders

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

(2009) Richard A Rudick et al.   LANCET NEUROLOGY

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis

(2008) Annie W. Chiu   ARCHIVES OF NEUROLOGY